aCCeleR8-001, NCT05101070: S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 274 | Japan, US | S-531011, pembrolizumab, KEYTRUDA® | Shionogi, Merck Sharp & Dohme LLC | Solid Tumors | 04/27 | 04/27 | | |